高危妊娠远程血压监测——随机对照试验研究方案(REMOTE CONTROL试验)
REMOTE CONTROL试验是一项在澳大利亚3家城市教学医院开展的实用型非盲随机对照试验,按1:1比例将高危妊娠孕妇分配至远程血压监测组或传统面对面门诊监测组,旨在评估远程血压监测的安全性、成本效益、对医疗资源利用的影响及终端用户满意度,并评价母婴结局。
要点
- 高危妊娠孕妇需频繁产前评估,远程血压监测可能减少门诊就诊和资源消耗。
- 该试验为实用型非盲随机对照试验,在澳大利亚3家城市教学医院招募,1:1分组。
- 试验旨在评估远程监测的安全性、成本效益、医疗资源利用及用户满意度。
核心结论
- 远程血压监测在新冠疫情期间得到广泛采用,但缺乏支持其优于传统面对面方式的稳健证据,对母婴结局的影响尚未见报告,亟需评估其在高危妊娠中的有效性。
研究设计与样本
- REMOTE CONTROL试验为实用型、非盲、随机对照试验,在澳大利亚3家城市教学医院招募高危妊娠孕妇,按1:1分配至远程血压监测组或传统面对面门诊监测组。
主要发现
- 该试验旨在评估远程血压监测的安全性、成本效益、对医疗资源利用的影响及终端用户满意度。
局限性
- 原文指出缺乏支持远程血压监测优于传统面对面方式的稳健证据,且对母婴结局的影响尚未见报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pregnant women at high risk for developing a hypertensive disorder of pregnancy require frequent antenatal assessments, especially of their blood pressure. This expends significant resources for both the patient and healthcare system. An alternative to in-clinic assessments is a remote blood pressure monitoring strategy, in which patients self-record their blood pressure at home using a validated blood pressure machine. This has the potential to be cost-effective, increase patient satisfaction, and reduce outpatient visits, and has had widespread uptake recently given the increased need for remote care during the ongoing COVID-19 pandemic. However robust evidence supporting this approach over a traditional face-to-face approach is lacking, and the impact on maternal and foetal outcomes has not yet been reported. Thus, there is an urgent need to assess the efficacy of remote monitoring in pregnant women at high risk of developing a hypertensive disorder of pregnancy. METHODS: The REMOTE CONTROL trial is a pragmatic, unblinded, randomised controlled trial, which aims to compare remote blood pressure monitoring in high-risk pregnant women with conventional face-to-face clinic monitoring, in a 1:1 allocation ratio. The study will recruit patients across 3 metropolitan Australian teaching hospitals and will evaluate the safety, cost-effectiveness, impact on healthcare utilisation and end-user satisfaction of remote blood pressure monitoring. DISCUSSION: Remote blood pressure monitoring is garnering interest worldwide and has been increasingly implemented following the COVID-19 pandemic. However, robust data regarding its safety for maternofoetal outcomes is lacking. The REMOTE CONTROL trial is amongst the first randomised controlled trials currently underway, powered to evaluate maternal and foetal outcomes. If proven to be as safe as conventional clinic monitoring, major potential benefits include reducing clinic visits, waiting times, travel costs, and improving delivery of care to vulnerable populations in rural and remote communities. TRIAL REGISTRATION: The trial has been prospectively registered with the Australian and New Zealand Clinical Trials Registry (ACTRN12620001049965p, on October 11th, 2020).
引用
- Rajkumar T, Freyne J, Varnfield M, et al. Remote blood pressure monitoring in high risk pregnancy - study protocol for a randomised controlled trial (REMOTE CONTROL trial). Trials. 2023. PMID: 37198630. doi:10.1186/s13063-023-07321-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。